VCM
ICPT

Versant Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Versant Capital Management’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-4
Closed – – 1772
2019
Q4 		$0 Buy
+4
New +$358 ﹤0.01% 1647

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Versant Capital Management's ICPT Position: Q1 2020 in Review

Versant Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2020, closing a stake of 4 shares.

Versant Capital Management first reported a position in ICPT in Q4 2019 and held it in 1 quarter. The position peaked at $0 in Q4 2019. 188 funds tracked by Wall St. Rank hold ICPT as of Q1 2020.

  • Versant Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • Versant Capital Management sold 4 Intercept Pharmaceuticals, Inc. shares in Q1 2020.
  • Versant Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2019 and held it in 1 quarter.
  • Versant Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $0 in Q4 2019.
  • 188 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2020.

Based on Versant Capital Management's 13F filing for Q1 2020, filed 17 Apr 2020.